Esperion Therapeutics (ESPR) Free Cash Flow Growth (5y) (2017 - 2026)
Esperion Therapeutics (ESPR) Free Cash Flow Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.71% |
| Dec 31, 2025 | 21.57% |
| Sep 30, 2025 | 45.18% |
| Jun 30, 2025 | -17.36% |
| Mar 31, 2025 | 20.11% |
| Dec 31, 2024 | 6.95% |
| Sep 30, 2024 | 9.26% |
| Jun 30, 2024 | 33.04% |
| Mar 31, 2024 | -10.09% |
| Dec 31, 2023 | -5.14% |
| Sep 30, 2023 | 12.43% |
| Jun 30, 2023 | 8.79% |
| Mar 31, 2023 | -4.69% |
| Dec 31, 2022 | -4.02% |
| Sep 30, 2022 | -3.60% |
| Jun 30, 2022 | -14.01% |
| Mar 31, 2022 | -2.58% |
| Dec 31, 2021 | -28.60% |
| Sep 30, 2021 | -37.05% |
| Jun 30, 2021 | -45.63% |